Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma

Jithma P. Abeykoon; David L. Murray; Isaiah Murray; Dragan Jevremovic; Gregory E. Otteson; Angela Dispenzieri; Bonnie K. Arendt; Surendra Dasari; Morie Gertz; Wilson I. Gonsalves; Taxiarchis V. Kourelis; Eli Muchtar; David Dingli; Rahma Warsame; Ronald S. Go; Martha Q. Lacy; Nelson Leung; Francis Buadi; Yi Lin; Robert A. Kyle; Vincent Rajkumar; Shaji Kumar; Prashant Kapoor

doi:10.1111/bjh.17195

Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma

Jithma P. Abeykoon, David L. Murray, Isaiah Murray, Dragan Jevremovic, Gregory E. Otteson, Angela Dispenzieri, Bonnie K. Arendt, Surendra Dasari, Morie Gertz, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Eli Muchtar, David Dingli, Rahma Warsame, Ronald S. Go, Martha Q. Lacy, Nelson Leung, Francis Buadi, Yi Lin, Robert A. KyleVincent Rajkumar, Shaji Kumar, Prashant Kapoor

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.

Original language	English (US)
Pages (from-to)	380-385
Number of pages	6
Journal	British journal of haematology
Volume	193
Issue number	2
DOIs	https://doi.org/10.1111/bjh.17195
State	Published - Apr 2021

Keywords

mass spectroscopy
measurable residual disease
prognosis

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.17195

Cite this

Abeykoon, J. P., Murray, D. L., Murray, I., Jevremovic, D., Otteson, G. E., Dispenzieri, A., Arendt, B. K., Dasari, S., Gertz, M., Gonsalves, W. I., Kourelis, T. V., Muchtar, E., Dingli, D., Warsame, R., Go, R. S., Lacy, M. Q., Leung, N., Buadi, F., Lin, Y., ... Kapoor, P. (2021). Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. British journal of haematology, 193(2), 380-385. https://doi.org/10.1111/bjh.17195

Abeykoon, JP, Murray, DL, Murray, I, Jevremovic, D, Otteson, GE, Dispenzieri, A, Arendt, BK, Dasari, S , Gertz, M , Gonsalves, WI , Kourelis, TV, Muchtar, E, Dingli, D, Warsame, R, Go, RS, Lacy, MQ, Leung, N, Buadi, F, Lin, Y, Kyle, RA, Rajkumar, V , Kumar, S & Kapoor, P 2021, 'Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma', British journal of haematology, vol. 193, no. 2, pp. 380-385. https://doi.org/10.1111/bjh.17195

@article{f5f9e634b0f448258d4fb4c6494ff7c3,

title = "Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma",

abstract = "Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.",

keywords = "mass spectroscopy, measurable residual disease, prognosis",

author = "Abeykoon, {Jithma P.} and Murray, {David L.} and Isaiah Murray and Dragan Jevremovic and Otteson, {Gregory E.} and Angela Dispenzieri and Arendt, {Bonnie K.} and Surendra Dasari and Morie Gertz and Gonsalves, {Wilson I.} and Kourelis, {Taxiarchis V.} and Eli Muchtar and David Dingli and Rahma Warsame and Go, {Ronald S.} and Lacy, {Martha Q.} and Nelson Leung and Francis Buadi and Yi Lin and Kyle, {Robert A.} and Vincent Rajkumar and Shaji Kumar and Prashant Kapoor",

note = "Funding Information: Prashant Kapoor, M.D. received Mayo Clinic Transplant Center Scholar Award to support this work. This work is also in part supported by NCI Myeloma SPORE grant 5P50 CA186781‐04. Funding Information: David L. Murray and Surendra Dasari have intellectual property rights encompassing the MASS‐FIX process which have been licensed to The Binding Site. Prashant Kapoor is a PI for research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen and Amgen. Advisory Board: Sanofi, Pharmacyclics, Cellectar and Karyopharm. Publisher Copyright: {\textcopyright} 2020 British Society for Haematology and John Wiley & Sons Ltd",

year = "2021",

month = apr,

doi = "10.1111/bjh.17195",

language = "English (US)",

volume = "193",

pages = "380--385",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma

AU - Abeykoon, Jithma P.

AU - Murray, David L.

AU - Murray, Isaiah

AU - Jevremovic, Dragan

AU - Otteson, Gregory E.

AU - Dispenzieri, Angela

AU - Arendt, Bonnie K.

AU - Dasari, Surendra

AU - Gertz, Morie

AU - Gonsalves, Wilson I.

AU - Kourelis, Taxiarchis V.

AU - Muchtar, Eli

AU - Dingli, David

AU - Warsame, Rahma

AU - Go, Ronald S.

AU - Lacy, Martha Q.

AU - Leung, Nelson

AU - Buadi, Francis

AU - Lin, Yi

AU - Kyle, Robert A.

AU - Rajkumar, Vincent

AU - Kumar, Shaji

AU - Kapoor, Prashant

N1 - Funding Information: Prashant Kapoor, M.D. received Mayo Clinic Transplant Center Scholar Award to support this work. This work is also in part supported by NCI Myeloma SPORE grant 5P50 CA186781‐04. Funding Information: David L. Murray and Surendra Dasari have intellectual property rights encompassing the MASS‐FIX process which have been licensed to The Binding Site. Prashant Kapoor is a PI for research studies for which Mayo Clinic has received funding from AbbVie, Takeda, Sanofi, Janssen and Amgen. Advisory Board: Sanofi, Pharmacyclics, Cellectar and Karyopharm. Publisher Copyright: © 2020 British Society for Haematology and John Wiley & Sons Ltd

PY - 2021/4

Y1 - 2021/4

N2 - Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.

AB - Measurable residual disease (MRD) assessment by marrow-based next-generation flow cytometry (NGF) following autologous stem cell transplantation (ASCT) may lead to false-negative results due to patchy marrow involvement and extramedullary disease in patients with multiple myeloma. We assessed the value of simultaneous MRD evaluation with NGF and serum matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MASS-FIX). Of all 61 complete responders who were NGF-negative for MRD, around day-100 post ASCT, 59% were MASS-FIX-positive. At median follow-up of 26 months, 69% of MASS-FIX(+)/NGF(−) patients were alive and progression-free versus 96% of MASS-FIX(-)/NGF(−) patients, P = 0·02. MASS-FIX, a simple peripheral blood-based assay complements marrow-based NGF to accurately prognosticate patients with myeloma.

KW - mass spectroscopy

KW - measurable residual disease

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85096705371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096705371&partnerID=8YFLogxK

U2 - 10.1111/bjh.17195

DO - 10.1111/bjh.17195

M3 - Article

C2 - 33216966

AN - SCOPUS:85096705371

SN - 0007-1048

VL - 193

SP - 380

EP - 385

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 2

ER -

Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this